Skip to Content

Lutathera Approval Status

  • FDA approved: No
  • Brand name: Lutathera
  • Generic name: lutetium Lu 177 dotatate
  • Company: Advanced Accelerator Applications S.A.
  • Treatment for: Neuroendocrine Carcinoma

Lutathera (lutetium Lu 177 dotatate) is a Lu-177-labeled somatostatin analogue peptide in development for the treatment of gastroenteropancreatic neuroendocrine tumors.

In December 2016, Advanced Accelerator Applications S.A. announced the receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Lutathera for the treatment of gastroenteropancreatic neuroendocrine tumors. The CRL referred to issues relating to the NETTER-1 and Erasmus clinical datasets, and a safety update on clinical and non-clinical studies was also requested.

Development Status and FDA Approval Process for Lutathera

Dec 21, 2016Advanced Accelerator Applications Receives Complete Response Letter from FDA for Lutathera, an Investigational Treatment for Neuroendocrine Tumors
Jun 27, 2016Advanced Accelerator Applications Announces FDA Priority Review for Lutathera
Oct 22, 2013AAA Reaches Halfway Recruitment Milestone of Cancer Patients in Lutathera Trial

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.